Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Germany-based Boehringer Ingelheim has renewed and expanded its license to a research platform with NextBio, a provider of scientific platform to aggregate and interpret large quantities of molecular and other life sciences data for research and clinical applications.
Subscribe to our email newsletter
According to the multi-year renewal agreement, the user base for NextBio is expanded across Boehringer Ingelheim’s global research organization.
NextBio president and chief executive officer Saeid Akhtari said, "This expanded license and broadened access to the NextBio Research platform is a strong endorsement of our technology’s value for enabling life scientists to quickly examine and understand their data in the context of published research worldwide."
The integration of proprietary analysis results with curated content enables researchers’ ability to design experiments, test hypotheses and validate results, resulting in improved target analysis, understanding of disease mechanisms, and analysis of results across species.
NextBio Research offers a platform for exploratory, preclinical and early translational research in drug discovery and biotechnology research, according to the company.